Please login to the form below

Not currently logged in

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

Daiichi AZ logos

AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering some impressive results in phase 2.

The phase 2 Destiny-Breast01 study investigated trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients, who had already received two or more prior HER2-targeting therapies.

For these late-stage patients, who have little treatment options left, the results are significant. Objective response rate reached 60.9% in patients treated with the ADC as a monotherapy, who had already received a median of six prior treatments for their metastatic disease.

On top of that, patients also achieved a disease control rate of 97.3% with a median duration of response of 14.8 months, and median progression-free survival of 16.4 months.

Although median overall survival had not yet been reached, AZ estimates a survival rate of 86% at one year – these results were consistent across all patient subgroups.

Jose Baselga“The clinically meaningful and durable responses seen among these patients illustrate the potential of trastuzumab deruxtecan to establish a new standard of care,” said José Baselga (pictured left), executive vice president of oncology R&D at AZ.

“These results are impressive, as women with this advanced stage of breast cancer have already endured multiple prior therapies for HER2-positive metastatic breast cancer,” he added.

The catch of this otherwise spotless data-set is the drug's safety profile – 13.6% of patients experienced confirmed treatment-related interstitial lung disease. Four deaths (2.2%) occurred due to ILD, making it clear that the drug can cause serious toxicities.

Although this could lead to a potential black-box warning on the label if the drug is approved, the benefit of a 60.9% response in patients who have already been through numerous treatments will likely outweigh the possible side-effects.

AZ paid $1.35bn upfront in a deal worth $6.9bn to add Daiichi's ADC to its fast-growing cancer business.

The partners picked up a priority review for the drug from the FDA in October, on the strength of data from the Destiny-Breast01 trial.

Its nearest rival in the area is Roche’s anti-HER2 ADC Kadcyla (trastuzumab emtansine). Both drugs work by combining the HER2-targeting of trastuzumab with a cell-killing chemotherapy component designed to improve its ability to kill breast cancer cells.

AZ/Daiichi’s drug is thought to be a more potent ADC than Roche’s drug because it carries a topoisomerase inhibitor rather than Kadcyla’s tubulin inhibitor – and that means it can carry a greater cytotoxic payload.

Kadcyla is the smallest in terms of sales in Roche’s HER2 franchise, with its sales falling behind those of Herceptin (trastuzumab) and Perjeta (pertuzumab).

Although AZ/Daiichi’s drug would be used a ways down the treatment pathway if approved, the partners have additional trials for the ADC in order to move it into earlier lines of treatment, to become a direct challenger to Roche’s Herceptin/Perjeta combination.

Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active HER2 inhibitor tucatinib.

Its HER2CLIMB trial evaluated the drug as an add-on therapy to Herceptin and Xeloda (capecitabine), a standard regimen for HER2-positive breast cancer patients who have already been treated with Herceptin, Perjeta and Kadcyla.

AZ and Daiichi Sankyo are looking at a possible approval for their drug in the second quarter of 2020.

Article by
Lucy Parsons

12th December 2019

From: Research



Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...